Marc de Garidel
Born1956 (age 67–68)
Aix-en-Provence, France
EducationÉcole Spéciale des Travaux Publics
Thunderbird School of Global Management
Harvard Business School
OccupationBusinessman
Known forFormer CEO, Ipsen (2010-16)
TitleCEO and Interim Board Chair Abivax
Term2016-
Honours Legion Honneur Chevalier ribbon Knight Legion of Honour (2008)

Marc de Garidel is a French businessman.[1] He is the non-executive chairman of the pharmaceutical company Ipsen and advises Mayroy, the Ipsen controlling holding company.[1][2][3][4][5]

Education

Marc de Garidel graduated from the École Spéciale des Travaux Publics, an engineering grandes écoles in Paris.[1][3][4] He received a business degree from the Thunderbird School of Global Management in Glendale, Arizona, US and an executive MBA from Harvard Business School in Boston, Massachusetts.[1][3][4]

Career

In 1983, he started his career at Eli Lilly and Company, where he worked in France, the United States and Germany.[1][3]

In 1995, he joined Amgen as vice president of finance and treasury for Europe.[1][3][4] In 1998, he became vice president, corporate controller and chief accounting officer of Amgen.[1][3] In 2000, he became vice president and general manager for France, in charge of Amgen France.[1][3] In 2006, he became vice president for Southwestern Europe, including France, Spain, Belgium and Portugal.[1][3] From 2007 to 2010, he served as vice president for Southern Europe, the Middle East, Asia and Latin America at Amgen.[1][3][4]

He was chairman and chief executive officer of Ipsen from November 2010 to July 2016.[1][3][4][5]

He was also president and spokesperson for G5 santé, a lobbying group for French pharmaceutical companies, including BioMérieux, Guerbet, Ipsen, the Laboratoire français du Fractionnement et des Biotechnologies, Laboratoires Pierre Fabre, Sanofi, Stallergenes and Laboratoires Théa.[5]

Effective July 2016, de Garidel has assumed the role of Ipsen non-executive chairman and has continued to sit on the board of directors. In addition, de Garidel will advise Mayroy, the Ipsen controlling holding company.[6] Previously, he was a director of several biotechnology companies, including vice-chairman of Vifor Pharma (Switzerland) between May 2017 and 2018 (formerly Galenica), of which he was member of the board since 2015.

In early 2018, de Garidel joined Corvidia Therapeutics, a biotech company based in Waltham, Massachusetts. In April 2018, he raised a 60M series B round led by Venrock & other top tier US & Europe venture capital funds. In June 2020, after its lead asset, Ziltivekimab, was near completion of its phase 2b program, the company was acquired for $2.1B including an upfront of $725M by Novo Nordisk in one of the largest transaction of the biotech sector in the midst of the COVID-19 epidemic.[7]

De Garidel is a director of Claris Biotherapeutics since July 2020. He joined AZTherapies as chief executive officer and board member in October 2020.[8]

Honours

 France: Knight of the Legion of Honour (2008)[9]

Bibliography

  • La Société du Médicament (2006)

References

  1. 1 2 3 4 5 6 7 8 9 10 11 "Marc M.P. de Garidel: Executive Profile & Biography". Bloomberg. Retrieved 4 November 2016.
  2. ↑ "(David Meek new CEO of Ipsen)" (PDF). Archived from the original (PDF) on 2016-09-23.
  3. 1 2 3 4 5 6 7 8 9 10 "Ipsen biography". Archived from the original on 2013-04-11.
  4. 1 2 3 4 5 6 "Management". Promethera Biosciences. Board of Directors & and (sic) founders. Archived from the original on 11 October 2014.
  5. 1 2 3 "Les membres du G5 santé" [The G5 Health] (in French). G5 Health.
  6. ↑ "David Meek appointed as Chief Executive Officer of Ipsen" (Press release). Ipsen. 11 July 2016 – via Business Wire.
  7. ↑ "CEO spotlight: CinCor's Marc de Garidel — Sofinnova Partners". sofinnovapartners.com. 2022-04-06. Retrieved 2022-12-13.
  8. ↑ "AZTherapies - Harnessing the Power of Neuro-Immunology - Marc de Garidel". AZTherapies. Retrieved 2022-12-13.
  9. ↑ "Ordre de la Légion d'honneur - Nominations, promotions et élévations du 11-07-2008". www.france-phaleristique.com. Retrieved 2022-12-13.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.